sábado, 5 de septiembre de 2020

New Spotlight on CDER Science on Rigorous Detection of Nitrosamine Contaminants in Metformin Products: Balancing Product Safety and Product Accessibility - Drug Information Update

https://www.fda.gov/drugs/news-events-human-drugs/rigorous-detection-nitrosamine-contaminants-metformin-products-balancing-product-safety-and-product?utm_campaign=New%20Spotlight%20on%20CDER%20Science%20-%20Rigorous%20Detection%20of%20Nitrosamine%20Contaminants%20in%20Metformin%20Products&utm_medium=email&utm_source=Eloqua
DDI Listserv Header Capsule
New Spotlight on CDER Science on Rigorous Detection of Nitrosamine Contaminants in Metformin Products: Balancing Product Safety and Product Accessibility
State-of-the-art research capabilities in CDER allow the FDA to respond appropriately to reports from around the globe that may allege drug product contamination. CDER expertise includes analytic methodologies that can verify the safety of products marketed for patient use and prevent the distribution of products that are in fact shown to contain contaminants. 

No hay comentarios: